Differential implications of gut-related metabolites on outcomes between heart failure and myocardial infarction

Israr, Muhammad Zubair; Salzano, Andrea; Sarmad, Sarir; Ng, Leong L; Suzuki, Toru

doi:10.1093/eurjpc/zwad305

Cited by 2 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A growing body of evidence is showing the association of metabolites deriving from several metabolic pathways with cardiovascular diseases [79]. For instance, choline, a precursor of microbiota-derived metabolites that promote vascular ageing, whose role was already demonstrated in hypertension, atherosclerosis, myocardial infarction [80], and heart failure [81,82], was investigated as a biomarker of PH of various etiologies. Specifically, high baseline choline levels (representative of a western diet [83]) were significantly associated with adverse outcomes in PAH patients, as well as with elevated NT-proBNP levels, higher WHO-FC, and a low cardiac output index [84].…”

Section: Role Of Biomarkers In the Prognosis Of Pahmentioning

confidence: 99%

Circulating Biomarkers in Pulmonary Arterial Hypertension: An Update

Correale,

Tricarico,

Bevere

et al. 2024

Biomolecules

Self Cite

View full text Add to dashboard Cite

Pulmonary arterial hypertension (PAH) is a rare subtype of group 1 pulmonary hypertension (PH) diseases, characterized by high pulmonary artery pressure leading to right ventricular dysfunction and potential life-threatening consequences. PAH involves complex mechanisms: vasoconstriction, vascular remodeling, endothelial dysfunction, inflammation, oxidative stress, fibrosis, RV remodeling, cellular hypoxia, metabolic imbalance, and thrombosis. These mechanisms are mediated by several pathways, involving molecules like nitric oxide and prostacyclin. PAH diagnosis requires clinical evaluation and right heart catheterization, confirming a value of mPAP ≥ 20 mmHg at rest and often elevated pulmonary vascular resistance (PVR). Even if an early and accurate diagnosis is crucial, PAH still lacks effective biomarkers to assist in its diagnosis and prognosis. Biomarkers could contribute to arousing clinical suspicion and serve for prognosis prediction, risk stratification, and dynamic monitoring in patients with PAH. The aim of the present review is to report the main novelties on new possible biomarkers for the diagnosis, prognosis, and treatment monitoring of PAH.

show abstract

Section: Role Of Biomarkers In the Prognosis Of Pahmentioning

confidence: 99%

Circulating Biomarkers in Pulmonary Arterial Hypertension: An Update

Correale,

Tricarico,

Bevere

et al. 2024

Biomolecules

Self Cite

View full text Add to dashboard Cite

show abstract

“…Therefore, understanding the interactions between the gut microbiome and heart failure is crucial for developing new therapeutic strategies [27]. Modulating the gut microbiota and targeting specific microbial metabolites represent potential avenues for treatment.…”

Section: Microbiome and Heart Failurementioning

confidence: 99%

The web of intrigue: unraveling the role of NETosis within the gut-microbiome-immune-heart axis in acute myocardial infarction and heart failure

Yasuda,

Deans,

Shankar

et al. 2024

Cardiovascular Endocrinology &Amp; Metabolism

View full text Add to dashboard Cite

This review summarizes the role of NETosis, or the release of neutrophil extracellular traps (NETs), and its interplay with the gut microbiome in acute myocardial infarction (AMI) and heart failure. NETosis contributes to inflammation, thrombosis, and atherothrombosis, all central to the pathophysiology of AMI and heart failure. NETosis can be activated by inflammation and dietary factors, indicating association with metabolic conditions. In cases of heart failure, NETosis is regulated by inflammatory molecules such as C-reactive protein (CRP), and Krüppel-like factor 2 (KLF2) – a protein that plays a role in controlling inflammation, and angiotensin II. Changes in the gut microbiome are linked to the severity and recovery of cardiac injury post-AMI and heart failure progression. The microbiome’s influence extends to immune modulation and inflammatory responses, potentially affecting NETosis.

show abstract

Differential implications of gut-related metabolites on outcomes between heart failure and myocardial infarction

Cited by 2 publications

References 18 publications

Circulating Biomarkers in Pulmonary Arterial Hypertension: An Update

Circulating Biomarkers in Pulmonary Arterial Hypertension: An Update

The web of intrigue: unraveling the role of NETosis within the gut-microbiome-immune-heart axis in acute myocardial infarction and heart failure

Contact Info

Product

Resources

About